Table 7 In vitro Susceptibility patterns of C. albicans and non-albicans Candida species to Fluconazole (25 μg), Nystatin (100 units) and Voriconazole (1 μg) (n = 54)
DRUGS | CANDIDA SPECIES | S n (%) | S-DD n (%) | R n (%) | Total (%) |
|---|---|---|---|---|---|
FLUCONAZOLE | C. albicans | 3 (21.4) | 4 (28.6) | 7 (50.0) | 14 (100.0) |
Non-albicans Candida | 7 (17.5) | 14 (35.0) | 19 (47.5) | 40 (100.0) | |
C. glabrata | 6 (19.4) | 13 (41.9) | 12 (38.7) | 31 (100.0) | |
C. krusei | 0 (0.0) | 0 (0.0) | 6 (100.0) | 6 (100.0) | |
C. parapsilosis | 1 (33.3) | 1 (33.3) | 1 (33.3) | 3 (100.0) | |
NYSTATIN | C. albicans | 0 (0.0) | 14 (100.0) | 0 (0.0) | 14 (100.0) |
Non-albicans Candida | 2 (5.0) | 33 (82.5) | 5 (12.5) | 40 (100.0) | |
C. glabrata | 0 (0.0) | 27 (87.1) | 4 (12.9) | 31 (100.0) | |
C. krusei | 0 (0.0) | 5 (83.3) | 1 (16.7) | 6 (100.0) | |
C. parapsilosis | 2 (66.7) | 1 (33.3) | 0 (0.0) | 3 (100.0) | |
VORICONAZOLE | C. albicans | 6 (42.9) | 1 (7.1) | 7 (50.0) | 14 (100.0) |
Non-albicans Candida | 21 (52.5) | 6 (15.0) | 13 (32.5) | 40 (100.0) | |
C. glabrata | 17 (54.8) | 3 (9.7) | 11 (35.5) | 31 (100.0) | |
C. krusei | 2 (33.3) | 3 (50.0) | 1 (16.7) | 6 (100.0) | |
C. parapsilosis | 2 (66.7) | 0 (0.0) | 1(.3) | 3 (100.0) |